PLN-74809 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Primary Sclerosing Cholangitis

Conditions

Primary Sclerosing Cholangitis

Trial Timeline

Jul 27, 2020 → Mar 18, 2024

About PLN-74809 + Placebo

PLN-74809 + Placebo is a phase 2 stage product being developed by Pliant Therapeutics for Primary Sclerosing Cholangitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04480840. Target conditions include Primary Sclerosing Cholangitis.

What happened to similar drugs?

20 of 20 similar drugs in Primary Sclerosing Cholangitis were approved

Approved (20) Terminated (6) Active (0)
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
Duloxetine + PlaceboEli LillyApproved
Eszopiclone + PlaceboSumitomo PharmaApproved
Eszopiclone + PlaceboSumitomo PharmaApproved
RosuvastatinAstraZenecaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT06097260Phase 2Terminated
NCT05621252Phase 2Completed
NCT04565249Phase 2Terminated
NCT04480840Phase 2Completed
NCT04396756Phase 2Completed

Competing Products

20 competing products in Primary Sclerosing Cholangitis

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
33
azenosertibZentalis PharmaceuticalsPhase 2
32
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
31
Rituximab, lenalidomideCelltrionPhase 2
42
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
40
CS-3150Daiichi SankyoPre-clinical
26
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
33
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Combination of bempedoic acid and ezetimibeDaiichi SankyoPre-clinical
33
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
18
Roxadustat + PlaceboAstellas PharmaPhase 3
32
Enzalutamide + ExemestaneAstellas PharmaPhase 2
35
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31